Project Grant R21CA297703
Award Date
7/16/25
Completion Date
6/30/27
Dollars Obligated
$392K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Pensilvania, EE. UU.
Similar Awards
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $554,188 to The Trustees of the University of Pennsylvania to develop novel silver telluride nanoparticle contrast agents for use in dual-energy mammography breast cancer screening. The goal is to create an improved contrast agent that addresses limitations of current iodine-based agents, providing stronger contrast, a longer imaging window, and better...
This federal Project Grant award of $226,704 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research to develop a novel nanoparticle heating system for cancer therapy. The project aims to use low-frequency ferromagnetic resonance to efficiently heat magnetic nanoparticles and deposit energy into cancer cells, while minimizing heating of surrounding normal tissue. The award was granted to the Dartmouth-Hitchcock Clinic, a non-profit...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Trustees of the University of Pennsylvania is focused on engineering a protein therapeutic to limit the transformation of the patient's own anti-tumor autoantibodies into highly potent T cell-redirecting antibodies, specifically within the tumor microenvironment. The $216,682 award, effective March 1, 2025 through February 28, 2027, aims to optimize the engineered protein therapeutic...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) totaling $227,906 will support the development of a novel technology for spatially resolved multi-omics sequencing of formalin-fixed paraffin-embedded (FFPE) tissue samples at the cellular level. The key products and services to be delivered under this award include: Developing spatial epigenome sequencing capabilities to measure gene expression and epigenetic characteristics directly in...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $546,625.00 to the University of Pittsburgh to develop a novel nanocarrier-based immunochemotherapy for the treatment of metastatic colorectal cancer (mCRC). The key products and services to be delivered include: Developing and characterizing a nanoparticle carrier capable of co-delivering small interfering RNA targeting the IRHOM1 protein and a prodrug conjugate of...
This Project Grant award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program provides $305,000 to support the development of a novel light-activatable nanoplatform for the targeted co-delivery of photodynamic therapy (PDT) and chemotherapy to treat peritoneal metastasis. The key objectives are to: 1) compare the pharmacokinetics and biodistribution of the nanoplatform following intravenous or intraperitoneal administration,...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Trustees of the University of Pennsylvania provides $227,906 to conduct research on the immunomodulatory effects of the FDA-approved drug Photofrin and other heme oxygenase (HO)-1 inducing agents for the treatment of malignant pleural mesothelioma (MPM). The research aims to 1) characterize the tumor control and antitumor immunity generated by Photofrin and other HO-1 inducing drugs,...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $137,322 to Trustees of Boston University to develop disulfated polyamidosaccharide (DISULPAS) nanoparticles for the targeted delivery of chemotherapeutics to metastasizing cancer cells. The goal is to create a synthetic fucoidan mimetic that can more consistently bind to the P-selectin protein, which is upregulated on many tumor cells and plays a key role in metastasis. The project will...
This $692,072 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will fund the development of a novel theranostic platform using PSMA-targeted poly(amidoamine) (PAMAM) dendrimers for the management of prostate cancer. The key products to be delivered include: PSMA-targeted theranostic agents that enable highly specific targeting, quantitative PET/CT imaging for patient selection, and delivery of potent antimitotic agents....
The National Cancer Institute (NCI) awarded a $406,258 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Georgia State University Research Foundation Inc. on July 15, 2025. The grant supports research to develop novel covalent anti-cancer drugs using phosphorus fluoride exchange (PFEX) click chemistry. The key objectives are to: 1) synthesize PFEX warheads with different substituents to optimize stability and reactivity, 2) compare PFEX warheads to α,β-unsaturated carbonyl warheads,...